A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE

<div>Differences in transcriptome samples between the TACE response and nonresponse groups in GSE104580. (a) The heat map shows the clustering of TACE responders and nonresponders. (b) The volcano map shows genes upregulated in both groups. The bubble diagram shows KEGG pathways enriched in the TACE (c) nonresponse and (d) response groups.</div>

Journal of Oncology

fig1

Figure 1

Figure 1: A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE 

Figure 1 | A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE 